Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot study.

De Souza A, Strober BE, Merola JF, Oliver S, Franks AG Jr.

J Drugs Dermatol. 2012 Oct;11(10):1224-6.

PMID:
23134988
2.
3.

Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.

Gottlieb AB, Matheson RT, Menter A, Leonardi CL, Day RM, Hu C, Schafer PH, Krueger JG.

J Drugs Dermatol. 2013 Aug;12(8):888-97.

PMID:
23986162
4.

An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast.

Gottlieb AB, Strober B, Krueger JG, Rohane P, Zeldis JB, Hu CC, Kipnis C.

Curr Med Res Opin. 2008 May;24(5):1529-38. doi: 10.1185/030079908X301866 . Epub 2008 Apr 16.

PMID:
18419879
5.

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.

Pathan E, Abraham S, Van Rossen E, Withrington R, Keat A, Charles PJ, Paterson E, Chowdhury M, McClinton C, Taylor PC.

Ann Rheum Dis. 2013 Sep 1;72(9):1475-80. doi: 10.1136/annrheumdis-2012-201915. Epub 2012 Sep 14.

PMID:
22984171
6.

Apremilast in psoriatic arthritis.

Schett G.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S98-100. Epub 2015 Oct 15. Review.

PMID:
26472278
7.

Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Schafer PH, Parton A, Gandhi AK, Capone L, Adams M, Wu L, Bartlett JB, Loveland MA, Gilhar A, Cheung YF, Baillie GS, Houslay MD, Man HW, Muller GW, Stirling DI.

Br J Pharmacol. 2010 Feb;159(4):842-55. doi: 10.1111/j.1476-5381.2009.00559.x. Epub 2009 Dec 24.

8.

Drug safety evaluation of apremilast for treating psoriatic arthritis.

Busa S, Kavanaugh A.

Expert Opin Drug Saf. 2015 Jun;14(6):979-85. doi: 10.1517/14740338.2015.1031743. Epub 2015 Mar 31. Review.

PMID:
25827658
9.

Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis.

Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD, Hochfeld M, Teng LL, Schett G, Lespessailles E, Hall S.

J Rheumatol. 2015 Mar;42(3):479-88. doi: 10.3899/jrheum.140647. Epub 2015 Jan 15.

10.

Apremilast: A Review in Psoriasis and Psoriatic Arthritis.

Deeks ED.

Drugs. 2015 Aug;75(12):1393-403. doi: 10.1007/s40265-015-0439-1. Review.

PMID:
26220911
11.

New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.

Palfreeman AC, McNamee KE, McCann FE.

Drug Des Devel Ther. 2013;7:201-10. doi: 10.2147/DDDT.S32713. Epub 2013 Mar 27. Review.

12.

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast.

Gooderham M, Papp K.

BioDrugs. 2015 Oct;29(5):327-39. Review.

13.

Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.

Schafer P.

Biochem Pharmacol. 2012 Jun 15;83(12):1583-90. doi: 10.1016/j.bcp.2012.01.001. Epub 2012 Jan 10.

PMID:
22257911
14.

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults.

Samrao A, Berry TM, Goreshi R, Simpson EL.

Arch Dermatol. 2012 Aug;148(8):890-7.

15.

Safety evaluation of apremilast for the treatment of psoriasis.

Dattola A, Del Duca E, Saraceno R, Gramiccia T, Bianchi L.

Expert Opin Drug Saf. 2017 Mar;16(3):381-385. doi: 10.1080/14740338.2017.1288714. Epub 2017 Feb 7.

PMID:
28132578
16.

[Rediscovery of thalidomide. Successful treatment of discoid lupus erythematosus].

Kuhn A, Hefter H, Ruzicka T, Lehmann P.

Hautarzt. 2001 Aug;52(8):726-33. German.

PMID:
11544946
17.

Apremilast in the treatment of psoriasis and psoriatic arthritis.

Gooderham M, Papp K.

Skin Therapy Lett. 2015 Sep-Oct;20(5):1-6. Review.

19.

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).

Edwards CJ, Blanco FJ, Crowley J, Birbara CA, Jaworski J, Aelion J, Stevens RM, Vessey A, Zhan X, Bird P.

Ann Rheum Dis. 2016 Jun;75(6):1065-73. doi: 10.1136/annrheumdis-2015-207963. Epub 2016 Jan 20.

Supplemental Content

Support Center